Screening for hepatocellular carcinoma: patient selection and perspectives by Fateen W, Ryder SD

Get full text

Healthcare costs of transarterial chemoembolization in the treatment of hepatocellular carcinoma by Fateen W, Khan F, O’Neill RJ, James MW, Ryder SD, Aithal GP

Get full text

Outcomes of National Survey of the Practice of Hepatocellular Carcinoma Surveillance by Scott RA, Cross TJS, Clarke C, Khan SA, Ryder SD, Franklin J, Aravinthan AD

Get full text

Utility of a buccal swab point-of-care test for the IFNL4 genotype in the era of direct acting antivirals for hepatitis C virus by Sy, A, McCabe, L, Hudson, E, Ansari, AM, Pedergnana, V, Lin, S-K, Santana, S, Fiorino, M, Ala, A, Stone, B, Smith, M, Nelson, M, Barclay, ST, McPherson, S, Ryder, SD, Collier, J, Barnes, E, Walker, AS, Pett, SL, Cooke, G

Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C by Cooke, GS, Pett, S, McCabe, L, Jones, C, Gilson, R, Verma, S, Ryder, SD, Collier, JD, Barclay, ST, Ala, A, Bhagani, S, Nelson, M, Ch'Ng, C, Stone, B, Wiselka, M, Forton, D, McPherson, S, Halford, R, Nguyen, D, Smith, D, Ansari, A, Dennis, E, Hudson, F, Barnes, EJ, Walker, AS

Variable short duration treatment versus standard treatment, with and without adjunctive ribavirin, for chronic hepatitis C: the STOP-HCV-1 non-inferiority, factorial RCT by Cooke, GS, Pett, SL, McCabe, L, Jones, C, Gilson, R, Verma, S, Ryder, SD, Collier, JD, Barclay, ST, Ala, A, Bhagani, S, Nelson, M, Ch'Ng, CL, Stone, B, Wiselka, M, Forton, D, McPherson, S, Halford, R, Nguygen, D, Smith, D, Ansari, MA, Ainscough, H, Dennis, E, Hudson, F, Barnes, EJ, Walker, AS